MaxCyte, Inc.

MaxCyte, Inc.

MXCT·NASDAQ

$1.23

+1.9%
HealthcareMedical - Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$131.76M
EPS-0.4200
P/E Ratio-2.93
Earnings Date08/12/2026

mxct

Net Cash Provided by Investing Activities

Last Annual Value

25.93M

3-Year CAGR

45%

5-Year CAGR

29%

10-Year CAGR

75%

MaxCyte, Inc.

MaxCyte, Inc. Competitors Analysis of Net Cash Provided by Investing Activities

MXCT · NASDAQ
CompanyNet Cash Provided by Investing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
25.93M
-22.2%N/AN/A 
41.23M
19.2%N/A39.2%
-66.77K
N/AN/AN/A
36.23M
816.9%N/A4.0%
HYPR logo
Hyperfine, Inc.
NASDAQ:HYPR
-1.19M
N/AN/AN/A
14.33M
-30.2%N/AN/A
-224.00K
N/AN/AN/A
-838.00K
N/AN/AN/A
OWLT logo
Owlet, Inc.
NYSE:OWLT
-943.00K
N/AN/AN/A
-542.00K
N/AN/AN/A
LNSR logo
LENSAR, Inc.
NASDAQ:LNSR
1.28M
N/AN/AN/A
MaxCyte, Inc.

MaxCyte, Inc. Fair Value Envelope

MXCT · NASDAQ

Our analysis suggests that MXCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.23, this represents a potential HIDDEN relative to our calculated worth for MaxCyte, Inc..

Intrinsic Value
Current Price: $1.23